Related Experiment Video
Updated: May 10, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
179
A Novel Serum Inflammation Risk-Index (SIRI-RT)-Driven Nomogram for Predicting Secondary Malignancy Outcomes
Sonia Gandhi1, Sudhir Chandna1, Vijayakumar Chinnadurai1
1Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India.
Cancers
|April 26, 2025
Summary
Predicting secondary cancers after radiation therapy is crucial for survivors. This study found that elevated serum inflammation scores can help predict the likelihood of developing these radiation-induced secondary cancers.
Area of Science:
- Oncology
- Medical Diagnostics
Background:
- Radiation therapy is a primary cancer treatment but can cause secondary tumors.
- Predicting radiation-induced secondary cancers is vital for improving cancer survivor outcomes.
- Research on serum inflammatory markers for predicting these secondary cancers is limited.
Purpose of the Study:
- To investigate serum-based inflammation prognostic scores as predictive tools for radiation-induced secondary malignancies.
- To develop a clinical utility nomogram for predicting secondary cancer occurrence after radiation therapy.
Main Methods:
- Retrospective analysis of a patient cohort with radiation-induced secondary malignancy from the MIMIC-IV database.
- Utilized SIRI-RT as a risk index to assess a serum-based inflammatory marker score.
- Identified confounding risk factors including Charlson comorbidity index, chemotherapy, and creatinine levels.
Main Results:
- A Radiation-Induced Secondary Malignancy (RISM) rate of 4.28% was observed in the MIMIC-IV cohort.
- The study assessed the efficacy of the developed risk score and nomogram.
- Significant confounding risk factors were identified.
Conclusions:
- Elevated serum-based inflammation prognostic scores can predict a higher likelihood of secondary malignancies post-radiation therapy.
- The developed nomogram serves as a clinical utility tool for predicting secondary cancer risk.
